967 related articles for article (PubMed ID: 32178558)
1. LncRNA LEF1-AS1 silencing diminishes EZH2 expression to delay hepatocellular carcinoma development by impairing CEBPB-interaction with CDCA7.
Gao J; Dai C; Yu X; Yin XB; Zhou F
Cell Cycle; 2020 Apr; 19(8):870-883. PubMed ID: 32178558
[TBL] [Abstract][Full Text] [Related]
2. Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2.
Zhang DY; Sun QC; Zou XJ; Song Y; Li WW; Guo ZQ; Liu SS; Liu L; Wu DH
J Exp Clin Cancer Res; 2020 Oct; 39(1):229. PubMed ID: 33121524
[TBL] [Abstract][Full Text] [Related]
3. Silencing of long noncoding RNA LEF1-AS1 prevents the progression of hepatocellular carcinoma via the crosstalk with microRNA-136-5p/WNK1.
Dong H; Jian P; Yu M; Wang L
J Cell Physiol; 2020 Oct; 235(10):6548-6562. PubMed ID: 32068261
[TBL] [Abstract][Full Text] [Related]
4. Long noncoding RNA LEF1-AS1 acts as a microRNA-10a-5p regulator to enhance MSI1 expression and promote chemoresistance in hepatocellular carcinoma cells through activating AKT signaling pathway.
Gao J; Dai C; Yu X; Yin XB; Zhou F
J Cell Biochem; 2021 Jan; 122(1):86-99. PubMed ID: 32786108
[TBL] [Abstract][Full Text] [Related]
5. Down-regulated lncRNA TP73-AS1 reduces radioresistance in hepatocellular carcinoma via the PTEN/Akt signaling pathway.
Song W; Zhang J; Xia Q; Sun M
Cell Cycle; 2019 Nov; 18(22):3177-3188. PubMed ID: 31564201
[No Abstract] [Full Text] [Related]
6. Overexpression of the long non-coding RNA SPRY4-IT1 promotes tumor cell proliferation and invasion by activating EZH2 in hepatocellular carcinoma.
Zhou M; Zhang XY; Yu X
Biomed Pharmacother; 2017 Jan; 85():348-354. PubMed ID: 27899259
[TBL] [Abstract][Full Text] [Related]
7. LncRNA DBH-AS1 facilitates the tumorigenesis of hepatocellular carcinoma by targeting miR-138 via FAK/Src/ERK pathway.
Bao J; Chen X; Hou Y; Kang G; Li Q; Xu Y
Biomed Pharmacother; 2018 Nov; 107():824-833. PubMed ID: 30142544
[TBL] [Abstract][Full Text] [Related]
8. ZSCAN16-AS1 expedites hepatocellular carcinoma progression via modulating the miR-181c-5p/SPAG9 axis to activate the JNK pathway.
Liu J; Liu R; Liu Y; Li L; Cao H; Liu J; Cao G
Cell Cycle; 2021 Jun; 20(12):1134-1146. PubMed ID: 34097562
[TBL] [Abstract][Full Text] [Related]
9. The lncRNA
Zhou N; Li S; Wu D; Zhang F; Tang F; Li Y
DNA Cell Biol; 2021 Oct; 40(10):1278-1289. PubMed ID: 34558987
[TBL] [Abstract][Full Text] [Related]
10. LncRNA FOXD2-AS1 plays an oncogenic role in hepatocellular carcinoma through epigenetically silencing CDKN1B(p27) via EZH2.
Xu K; Zhang Z; Qian J; Wang S; Yin S; Xie H; Zhou L; Zheng S
Exp Cell Res; 2019 Jul; 380(2):198-204. PubMed ID: 31004581
[TBL] [Abstract][Full Text] [Related]
11. Long noncoding RNA DDX11-AS1 epigenetically represses LATS2 by interacting with EZH2 and DNMT1 in hepatocellular carcinoma.
Li Y; Zhuang W; Huang M; Li X
Biochem Biophys Res Commun; 2019 Jul; 514(4):1051-1057. PubMed ID: 31097223
[TBL] [Abstract][Full Text] [Related]
12. LncRNA DARS-AS1 aggravates the growth and metastasis of hepatocellular carcinoma via regulating the miR-3200-5p-Cytoskeleton associated protein 2 (CKAP2) axis.
Feng Y; Wei G; Zhang L; Zhou H; Wang W; Guo P; Cheng C; Ji L; Cai Q; Feng Y; Tu H
Bioengineered; 2021 Dec; 12(1):8217-8232. PubMed ID: 34596006
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of lncRNA SBF2-AS1 inhibits hepatocellular carcinoma proliferation and migration by regulating the miR-361-5p/TGF-β1 signaling pathway.
Wu YH; Yu B; Chen WX; Ai X; Zhang W; Dong W; Shao YJ
Aging (Albany NY); 2021 Aug; 13(15):19260-19271. PubMed ID: 34341185
[TBL] [Abstract][Full Text] [Related]
14. Long noncoding RNA ZFPM2-AS1 acts as a miRNA sponge and promotes cell invasion through regulation of miR-139/GDF10 in hepatocellular carcinoma.
He H; Wang Y; Ye P; Yi D; Cheng Y; Tang H; Zhu Z; Wang X; Jin S
J Exp Clin Cancer Res; 2020 Aug; 39(1):159. PubMed ID: 32795316
[TBL] [Abstract][Full Text] [Related]
15. LncRNA CDKN2B-AS1 promotes tumor growth and metastasis of human hepatocellular carcinoma by targeting let-7c-5p/NAP1L1 axis.
Huang Y; Xiang B; Liu Y; Wang Y; Kan H
Cancer Lett; 2018 Nov; 437():56-66. PubMed ID: 30165194
[TBL] [Abstract][Full Text] [Related]
16. Combination of curcumin with N-n-butyl haloperidol iodide inhibits hepatocellular carcinoma malignant proliferation by downregulating enhancer of zeste homolog 2 (EZH2) - lncRNA H19 to silence Wnt/β-catenin signaling.
Khan H; Ni Z; Feng H; Xing Y; Wu X; Huang D; Chen L; Niu Y; Shi G
Phytomedicine; 2021 Oct; 91():153706. PubMed ID: 34517264
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
Song H; Yu Z; Sun X; Feng J; Yu Q; Khan H; Zhu X; Huang L; Li M; Mok MTS; Cheng ASL; Gao Y; Feng H
EBioMedicine; 2018 Sep; 35():155-166. PubMed ID: 30150059
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of long non-coding RNA WT1-AS or silencing of PIK3AP1 are inhibitory to cervical cancer progression.
Tong W; Zhang H
Cell Cycle; 2021 Dec; 20(24):2583-2596. PubMed ID: 34839795
[TBL] [Abstract][Full Text] [Related]
19. lncRNA RBM5-AS1 promotes cell proliferation and invasion by epigenetically silencing miR-132/212 in hepatocellular carcinoma cells.
Mu JY; Tian JX; Chen YJ
Cell Biol Int; 2021 Nov; 45(11):2201-2210. PubMed ID: 34019714
[TBL] [Abstract][Full Text] [Related]
20. LncRNA TTN-AS1 intensifies sorafenib resistance in hepatocellular carcinoma by sponging miR-16-5p and upregulation of cyclin E1.
Zhou Y; Huang Y; Dai T; Hua Z; Xu J; Lin Y; Han L; Yue X; Ho L; Lu J; Ai X
Biomed Pharmacother; 2021 Jan; 133():111030. PubMed ID: 33378944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
